Jessica Mandrioli

Jessica Mandrioli

Coordinator and Principle Investigator

Since 2007 Dr. Mandrioli is the chief of the Multidisciplinary Centre for MND in Modena, Italy, a referral centre for diagnosis and treatment of MND and follows 250 patients every year. She created and has been coordinating the population based Registry of ALS in Modena since 2000, and in Emilia Romagna Region (4.4 million inhab.) since 2009. This Registry collects data on patients from 17 Italian neurological centres. She carried out several epidemiological studies on ALS in Italy. She took part, together with ITALSGEN Consortium, in several studies on genetics of ALS that led to the isolation of new genes (including VCP, C9ORF72, MATRIN3, KIF5A), and to pharmacological clinical trials in ALS. She coordinates clinical trials on ALS (currently: RAP-ALS, co-ALS, FETR-ALS).  She was coordinator of the Italian Study Group on MND from 2013 to 2017. She has published in over 100 peer-reviewed scientific journals and her work is highly cited by other scientists.

Connect
Connect trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial

This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.

Read more
Active
Phase iii

VALOR study

Industry trial

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more